Patent · US Active

Triterpene saponins, methods of synthesis and uses thereof

US9718850B2 · kind B2 · utility

11Cited by

6References

4Claims

0Family size

Assignee

MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH · US

Inventors

David Y. Gin · New York, US
Michelle Adams · New York, US
Kai Deng · Guilderland, US
Philip O. Livingston · New York, US
Govindaswami Ragupathi · New York, US
Eric CHEA · Great Neck, US
Alberto Fernandez-Tejada · Kingston, US
Lars NORDSTROEM · New York, US
William WALKOWICZ · Brooklyn, US
Jeffrey GARDNER · New York, US
Derek Shieh Tan · New York, US

Key dates

Filing date	Sep 24, 2014
Grant date	Aug 1, 2017
Priority date	—
Expiry date	Dec 3, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.